Healthcare

Peptide Therapeutics Market is Poised to be Worth US$ 46.6 Bn By The End Of 2024

The global market for peptide therapeutics is competitive in nature with a moderate level of consolidation, states a new market research study by Transparency Market Research. The leading players in the market are focusing on research and development activities, which are anticipated to generate promising growth opportunities for the market players in the next few years. Some of the leading players operating in the peptide therapeutics market across the globe are Eli Lilly, Teva, Novo Nordisk, and Sanofi..According to the market research study by Transparency Market Research, in 2015, the global market for peptide therapeutics was worth US$ 21.3 bn and is projected to reach a value of US$ 46.6 bn by the end of 2024. The market is predicted to register a promising 9.10% CAGR between 2016 and 2024.

Request a Sample of Peptide Therapeutics Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418

  • Presence of Leading Players to Drive North America Peptide Therapeutics Market

The global market for peptide therapeutics has been classified on the basis of geography, among which North America is anticipated to account for a large share of the global market in the next few years. In the last few years, this region led the global market and is projected to remain in the similar position in the near future. The high growth of this region can be attributed to the rapid development of the healthcare infrastructure and the introduction of advanced peptide therapeutics. In addition to this, the presence of a large number of players operating in this region and the increasing emphasis on innovations and developments are some of the other factors that are projected to enhance the growth of the market in the near future.

This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Peptide Therapeutics Market (Application – Cancer, Metabolic, CVD, Respiratory, GIT, Anti-infective, Dermatology, CNS, and Renal; Route of Administration – Parenteral and Oral; Type – Innovative and Generic; Technology – Liquid Phase, Solid Phase, and Hybrid Phase; Type of Molecule – Vasopressin, Somatostatin, Calcitonin, and Natriuretic, Immunopeptide; API Peptide Type – In-house and CMO) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”

Tags

Related Articles

Close